• $2.2M
    Market Cap
  • -39.04%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 85
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

What's Going On With Bluejay Diagnostics Shares On Wednesday?

Bluejay Diagnostics (BJDX) shares traded down 1.84% on Wednesday despite positive developments. The company announced a private placement raising up to $23.6 million ($8.5M upfront plus $15.1M from warrant exercises) to extend cash runway into early 2027 ahead of FDA submission. The company also partnered with Argonaut Manufacturing Services to establish U.S.-based manufacturing capabilities for its Symphony sepsis testing platform. While the stock showed strong momentum (77.52 score), the recent price action suggests caution as it approaches overbought conditions.

06/03/2026, 11:48 AM • Benzinga

Peers

Statistics

More
Day Range
$3.71
$7.00
$4.34
1-Year Range
$0.65
$4.34
$4.34
Latest Close$4.34
Change
+$2.17 (+50.00%)
Volume74,418,659
Market Cap$2.2M
Shares Outstanding1.0M
P/E (TTM)-0.10
Diluted EPS (TTM)-$21.27
Enterprise Value-$1.5M

Information as of 06/02/2026

Company Profile

BLUEJAY DIAGNOSTICS INC
https://bluejaydx.com
$2.2M
Market Cap
-$6.9M
Net Income
Sector: Healthcare
Industry: Medical Devices
360 Massachusetts Avenue, Acton, MA, United States, 01720
844 327 7078

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Key Executives

  • Indranil Dey
  • Mark W. Feinberg
  • Kevin Vance

Current Ownership Distribution

  • Institutions1.3M (56.38%)
  • Mutual Funds671,328 (29.96%)
  • Insiders306,056 (13.66%)
  • Other0 (0.00%)